Sanofi (SNY) Completes the Acquisition of Vicebio

Group 1 - Sanofi has completed the acquisition of Vicebio, a clinical-stage biotechnology company focused on multi-pathogen vaccines for respiratory viral infections [1][2] - The acquisition includes Vicebio's early-stage vaccine candidate for respiratory syncytial virus and human metapneumovirus, enhancing Sanofi's vaccine design and development capabilities through Vicebio's Molecular Clamp technology [2] - Sanofi's Dupilumab, developed in collaboration with Regeneron, has received European Commission approval for treating moderate-to-severe chronic spontaneous urticaria in patients aged 12 and above, marking it as a first-line targeted treatment option [3][4] Group 2 - The approval of Dupilumab was based on positive Phase 3 study results, demonstrating symptom reduction at 24 weeks compared to placebo, with a significant addressable market of over 270,000 adults and adolescents in the EU suffering from chronic spontaneous urticaria [4] - Sanofi operates in three segments: Pharmaceuticals, Consumer Healthcare, and Vaccines, focusing on research, production, and distribution of pharmaceutical products [4]